-
Regulatory February 23, 2024 EnglishINITIATOR PHARMA: YEAR END REPORT 2023
-
Regulatory February 21, 2024 EnglishMAC Clinical Research converts its receivable into shares in Initiator Pharma
-
Regulatory January 23, 2024 EnglishIssuance of new shares and directed share buyback, as well as the sale of shares in connection with the long-term incentive program for 2021
-
Regulatory February 23, 2024 EnglishINITIATOR PHARMA: YEAR END REPORT 2023
-
Regulatory November 10, 2023 EnglishINITIATOR PHARMA: Q3 2023 REPORT
-
Regulatory August 25, 2023 EnglishINITIATOR PHARMA: Q2 2023 REPORT
Share
Initiator Pharma Numbers
-
Expected Number of men affected by Erectile Dysfunction worldwide by 2025 322 million
-
Number of people worldwide that are diagnosed with Trigeminal Neuralgia every year: 15000
-
Men with Erectile Dysfunction who do not respond to drug therapy 40 %
Initiator Pharma currently has a portfolio of five projects, of which three are in clinical development and two are in preclinical development.
CEO letter
2023 has so far been an exciting and stimulating year for Initiator Pharma, where we have achieved multiple important milestones across our development pipeline. Our most important milestone, the positive statistically significant and clinically relevant efficacy data with pudafensine from the completed Phase IIb trial in organic ED, was announced just after the end of the period.